Shield Therapeutics "really starting to fire on all cylinders"

(via NewsDirect)

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) CEO Greg Madison speaks to Thomas Warner from Proactive after the commercial-stage specialty pharmaceutical company released a business update containing plenty of new information about its performance during the second quarter.

Madison gives an overview of the update, highlighting strong US sales growth for its Accrufer/Feraccru iron deficiency treatment as a result of the commercial expansion with Viatris that was completed in May, which brought the combined sales team to 100 people. He stresses that the team is "really starting to fire on all cylinders" but "hasn't really hit full stride yet...I think there's more that we can do and we're constantly looking at how we tweak the business and what adjustments we can make to further that growth - but [we're] off to a really nice start."

He also mentions a new marketing campaign and the addition of Andy Hurley as Chief Commercial Officer, who he describes as a "veteran on the commercial side... I couldn't be more pleased with his performance."

Contact Details

Proactive UK Ltd

[phone]

[e-mail]

Copyright (c) 2023 TheNewswire - All rights reserved.

Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases